Subcutaneous Furosemide in Heart Failure
Parenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer “hospital-strength” diuresis for outpatient use, including self-...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2018-02-01
|
| Series: | JACC: Basic to Translational Science |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2452302X17302632 |
| _version_ | 1818030957818544128 |
|---|---|
| author | Domenic A. Sica, MD Pieter Muntendam, MD Rene L. Myers, PhD Jozine M. ter Maaten, MD, PhD Mark E. Sale, MD Rudolf A. de Boer, MD, PhD Bertram Pitt, MD |
| author_facet | Domenic A. Sica, MD Pieter Muntendam, MD Rene L. Myers, PhD Jozine M. ter Maaten, MD, PhD Mark E. Sale, MD Rudolf A. de Boer, MD, PhD Bertram Pitt, MD |
| author_sort | Domenic A. Sica, MD |
| collection | DOAJ |
| description | Parenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer “hospital-strength” diuresis for outpatient use, including self-administration at home. Subcutaneous infusion using a biphasic delivery profile resulted in complete bioavailability (99.65%) and equivalent diuresis when compared with intravenous administration. Subcutaneous administration of buffered furosemide was well tolerated with no evidence of any drug-induced skin reactions. Subcutaneous infusion of buffered furosemide in the outpatient setting or home may help to reduce the burden of heart failure. |
| first_indexed | 2024-12-10T05:43:50Z |
| format | Article |
| id | doaj.art-e5d9db168ccc4c378272e397259e617b |
| institution | Directory Open Access Journal |
| issn | 2452-302X |
| language | English |
| last_indexed | 2024-12-10T05:43:50Z |
| publishDate | 2018-02-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JACC: Basic to Translational Science |
| spelling | doaj.art-e5d9db168ccc4c378272e397259e617b2022-12-22T02:00:14ZengElsevierJACC: Basic to Translational Science2452-302X2018-02-0131253410.1016/j.jacbts.2017.10.001Subcutaneous Furosemide in Heart FailureDomenic A. Sica, MD0Pieter Muntendam, MD1Rene L. Myers, PhD2Jozine M. ter Maaten, MD, PhD3Mark E. Sale, MD4Rudolf A. de Boer, MD, PhD5Bertram Pitt, MD6Virginia Commonwealth University Health System, Richmond, VirginiascPharmaceuticals, Inc, Burlington, MassachusettsscPharmaceuticals, Inc, Burlington, MassachusettsDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsNuventra Inc, Research Triangle Park, North CarolinaDepartment of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the NetherlandsCardiology Division, University of Michigan School of Medicine, Ann Arbor, MichiganParenteral diuretics form the cornerstone of decongestion in heart failure. However, parenteral therapy routinely requires emergency room or inpatient care. A novel buffered furosemide formulation with neutral pH was developed to offer “hospital-strength” diuresis for outpatient use, including self-administration at home. Subcutaneous infusion using a biphasic delivery profile resulted in complete bioavailability (99.65%) and equivalent diuresis when compared with intravenous administration. Subcutaneous administration of buffered furosemide was well tolerated with no evidence of any drug-induced skin reactions. Subcutaneous infusion of buffered furosemide in the outpatient setting or home may help to reduce the burden of heart failure.http://www.sciencedirect.com/science/article/pii/S2452302X17302632diuresisfurosemideheart failurepharmacokineticssubcutaneous |
| spellingShingle | Domenic A. Sica, MD Pieter Muntendam, MD Rene L. Myers, PhD Jozine M. ter Maaten, MD, PhD Mark E. Sale, MD Rudolf A. de Boer, MD, PhD Bertram Pitt, MD Subcutaneous Furosemide in Heart Failure JACC: Basic to Translational Science diuresis furosemide heart failure pharmacokinetics subcutaneous |
| title | Subcutaneous Furosemide in Heart Failure |
| title_full | Subcutaneous Furosemide in Heart Failure |
| title_fullStr | Subcutaneous Furosemide in Heart Failure |
| title_full_unstemmed | Subcutaneous Furosemide in Heart Failure |
| title_short | Subcutaneous Furosemide in Heart Failure |
| title_sort | subcutaneous furosemide in heart failure |
| topic | diuresis furosemide heart failure pharmacokinetics subcutaneous |
| url | http://www.sciencedirect.com/science/article/pii/S2452302X17302632 |
| work_keys_str_mv | AT domenicasicamd subcutaneousfurosemideinheartfailure AT pietermuntendammd subcutaneousfurosemideinheartfailure AT renelmyersphd subcutaneousfurosemideinheartfailure AT jozinemtermaatenmdphd subcutaneousfurosemideinheartfailure AT markesalemd subcutaneousfurosemideinheartfailure AT rudolfadeboermdphd subcutaneousfurosemideinheartfailure AT bertrampittmd subcutaneousfurosemideinheartfailure |